Dr. Surendra Rajpurohit

Dr Rajpurohit's Lab is working on Experimental Therapeutics in Glioblastoma and Cardio-oncology using in vivo transparent transgenic zebrafish and mouse models, which includes high-throughput (HT) drug discovery, repurposing of FDA-approved drugs, identification of novel hit and lead drugs, drug validation, and drug toxicity in glioblastoma and cardio-oncology therapeutics. Dr Rajpurohit's Lab has developed and established an in vivo transparent transgenic cellular phenotype model of zebrafish to study the cell death process (Annexin5 and Inflammatory activity NFkB in the microglia-resident macrophage of the brain and cardiac myocytes). In cardio-oncology research, the focus is on developing a transparent transgenic zebrafish model to study Annexin-5 and NF-kB activity in normal and inflamed cardiac myocytes. In glioblastoma research, the lab determines the role of NFkB and microglia function in normal healthy status and in glioblastomas, using a mouse and zebrafish model. He is establishing the role of Annexin-5 and NF-kB activity in cardiovascular function under normal conditions and in metabolic aberration, developing homozygous Casper/ myl7:RFP; annexin-5:YFP/NF-kB:GFP transgenic zebrafish. Dr Rajpurohit designed and established the novel whole-organism-based ARQiv (automated reporter-based quantitative in vivo HT screen) platform. This novel device facilitates large-scale HT drug or chemical screens to find the hit and lead drugs for targeted disease modules.